The idea of using mesenchymal stem cells (MSCs) as vectors for anti-tumour ligand delivery, such as tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), has emerged as one of the avenues of cytotherapy in cancer treatment, as these cells were shown to home the tumour site and deliver targeted therapies. The gene discussed is TNFSF10; the disease is cancer.